Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target

Aptose Biosciences Inc. -2.31%

Aptose Biosciences Inc.

APTO

1.27

-2.31%

Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ: APTO) with a Overweight and maintains $5 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via